© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Strategic Partnership and Optional Merger Agreement to Develop Antibody Drug Conjugates and Bi-Speci
Posted 8th January 2016 • 1 min read

Strategic Partnership and Optional Merger Agreement to Develop Antibody Drug Conjugates and Bi-Speci

Zymeworks Inc. and Kairos Therapeutics Inc., both privately-held biotech companies headquartered in Vancouver, announced today they have entered into a strategic partnership.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.


You Might Also Like
Read Full PostRead - Eye Icon
A Sunny Year for the Sunshine State
Legal
02/02/2016A Sunny Year for the Sunshine State

Yolofsky Law is a business law firm that assists clients in both the boardroom and courtroom.

Read Full PostRead - Eye Icon
Bank Cyber-Attacks Highlight the Need to Simulate ‘War Games’, Says KPMG
Innovation
18/02/2015Bank Cyber-Attacks Highlight the Need to Simulate ‘War Games’, Says KPMG

KPMG's comment on news showing $1bn (£648m) has been stolen in cyber-attacks since 2013.

Read Full PostRead - Eye Icon
Aberdeen Asset Management Acquisition of Arden Asset Management
M&A
13/08/2015Aberdeen Asset Management Acquisition of Arden Asset Management

Aberdeen Asset Management Acquisition of Arden Asset Management



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow